Capricor Therapeutics, Inc. CAPR R2K
Healthcare · Biotechnology · United States
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
READ MORE ›$29.96
+202.93% 1Y
Market & Price
Market Cap
$1.74B
Current Price
$29.96
High / Low (52W)
$35.34 / $4.60
Beta
0.48
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
0.38
Book Value
$4.83
Price to Book
6.20
P/S
-
EV/EBITDA
-12.48
Dividend Yield
-
Profitability & Returns
ROCE
-31.86%
ROE
-56.40%
ROA
-31.23%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.59
EPS (TTM)
$-2.32
Balance Sheet & Liquidity
Debt/Equity
0.05
Quick Ratio
8.28
Current Ratio
8.42
Debt
$14.78M
Total Assets
$355.95M
Current Assets
$322.94M
Working Capital
$287.10M
Ownership
Promoter Holding
9.47%
Chg in Prom Hold
-
FII / Inst Holding
59.70%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.47B
Total Revenue (TTM)
-
EBITDA
$-117.91M
Free Cash Flow
$-70.47M
Operating Cash Flow
$-92.63M
Shares Outstanding
57.91M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-33.33%
Profit 5Y
-87.33%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Earnings shrank at -87.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CAPR Capricor Therapeutics, Inc. R2K | 29.96 | - | $1.74B | - | -31.86% | -56.40% | -33.33% | -87.33% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.43K | 1.04M | 1.04M | 1.30M | 1.79M | 1.29M | 1.31M | 1.22M | 1.13M | 746.78K | 880.81K | 996.46K | 313.27K | 400.07K | 403.96K | 219.25K | 230.50K | 410.35K | 142.07K | 185.69K | 49.86K | 16.86K | 40.82K | 204.08K | - | - | - | 1.59M | 2.99M | 3.92M | 6.19M | 4.91M | 3.97M | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.98M | 27.72M | 26.28M | 29.16M | 36.77M |
| Operating Income | -1.49M | -1.19M | -1.48M | -1.49M | -3.41M | -3.06M | -2.85M | -4.21M | -4.61M | -5.24M | -3.57M | -3.38M | -2.64M | -3.69M | -4.16M | -4.17M | -2.56M | -2.07M | -1.63M | -2.11M | -3.49M | -3.91M | -5.16M | -5.08M | -4.31M | -7.83M | -7.32M | -6.48M | -8.18M | -7.75M | -6.86M | -10.27M | -11.59M | - | - | -24.98M | -27.72M | -26.28M | -29.16M | -36.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.58M | -27.23M | -25.79M | -22.51M | -36.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.39M | -25.91M | -24.57M | -30.17M | -33.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 0 |
| Net Income | -1.55M | -1.21M | -1.53M | -1.54M | -3.48M | -3.12M | -2.91M | -4.27M | -4.69M | -5.33M | -3.67M | -3.47M | -2.73M | -3.67M | -4.12M | -4.14M | -2.52M | -2.05M | -1.61M | -2.08M | -3.48M | -3.91M | -5.15M | -4.75M | -3.93M | -7.82M | -7.11M | -6.37M | -7.77M | -7.37M | -6.39M | -9.79M | -11.00M | - | - | -24.39M | -25.91M | -24.57M | -30.17M | -33.94M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.23 | -0.23 | -0.23 | -0.21 | -0.17 | -0.32 | -0.29 | -0.26 | -0.31 | -0.29 | -0.25 | -0.31 | -0.35 | - | - | -0.53 | -0.57 | -0.54 | -0.62 | -0.59 |
| R&D Expense | 1.01M | 1.37M | 1.86M | 1.97M | 3.81M | 3.43M | 3.19M | 4.34M | 4.31M | 4.73M | 3.26M | 3.13M | 1.86M | 2.70M | 3.39M | 3.13M | 1.81M | 1.64M | 857.76K | 1.16M | 1.93M | 2.63M | 3.30M | 3.50M | 2.51M | 5.12M | 4.97M | 5.50M | 7.66M | 8.82M | 10.03M | 11.10M | 12.50M | 11.81M | - | 18.92M | 22.05M | 20.36M | - | 27.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.35M | 195.50K | 503.23K | 4.79M | 5.52M | 4.00M | 2.67M | 1.67M | 1.01M | 310.25K | - | 2.55M | 25.18M | 22.27M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.25M | 49.26M | 64.83M | 108.14M |
| Operating Income | - | - | - | - | -6.29M | -4.90M | -2.10M | -6.90M | -6.02M | -12.61M | -16.98M | -12.86M | -15.33M | -7.73M | -13.69M | - | -29.70M | -24.08M | -42.56M | -108.14M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.16M | -23.01M | -39.04M | -100.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 3.05M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.02M | -22.29M | -40.47M | -105.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.60K | 1.60K |
| Net Income | -1.17M | -979.08K | -630.86K | -148.97K | -1.06M | -1.15M | -2.07M | -8.89M | -6.22M | -12.86M | -18.81M | 2.43M | -15.19M | -7.64M | -13.66M | - | -29.02M | -22.29M | -40.47M | -105.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -1.01 | 0.09 | -0.52 | - | -0.88 | - | -1.18 | -0.83 | -1.15 | -2.26 |
| R&D Expense | - | - | - | - | 4.08M | 4.14M | 2.63M | 5.20M | 7.79M | 13.76M | 16.04M | 10.77M | 12.07M | 5.14M | 8.46M | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M |
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -87.33% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +202.93% |
| 6 Months: | +551.30% |
| 3 Months: | +7.27% |
| 1 Month: | -7.70% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2005 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | 3.67M | 1.37M | 5.42M | 5.54M | 13.63M | 16.07M | 18.75M | 16.27M | 9.25M | 11.11M | 34.62M | - | 50.09M | 58.73M | 170.48M | 355.95M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.89M | 50.86M | 163.39M | 322.94M |
| Cash & Equivalents | 0 | - | - | - | - | 3.18M | 3.38M | 1.55M | 170.11K | 1.73M | 8.03M | 5.57M | 3.20M | 6.14M | 4.26M | 3.90M | 32.67M | - | 9.60M | 14.69M | 11.29M | 287.85M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 547.58K | 10.37M | 10.37M | 59.17K |
| Total Liabilities | - | - | - | - | - | - | - | 541.45K | 529.17K | 6.07M | 19.88M | 17.10M | 22.75M | 5.05M | 4.63M | 4.27M | 6.42M | - | 38.31M | 36.13M | 25.02M | 50.16M |
| Current Liabilities | - | - | - | - | - | - | 1.07M | 541.45K | 529.17K | 2.05M | 6.30M | 6.53M | 4.90M | 1.67M | 1.26M | 897.99K | 2.97M | - | 23.59M | 31.27M | 21.03M | 35.84M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.56M | 2.24M | 1.45M | 14.52M |
| Total Equity | 0 | 0 | 1.84M | 863.17K | 252.55K | 911.77K | 1.79M | 1.66M | 4.89M | -534.88K | -6.25M | -1.03M | -4.00M | 11.23M | 4.62M | 6.84M | 28.20M | - | 11.79M | 22.60M | 145.46M | 305.79M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.24M | 31.15M | 45.58M | 57.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.32M | -4.65M | -2.19M | - | - | - | -14.45M | -14.23M | -13.86M | -6.82M | -10.05M | - | 4.92M | -25.60M | -40.00M | -69.81M |
| Investing Cash Flow | -2.21K | -1.99K | 0 | - | - | - | -5.19M | 4.98M | 4.67M | -3.00M | 5.44M | - | -35.07M | 5.11M | -116.18M | 97.48M |
| Financing Cash Flow | 4.52M | 2.31M | 1.19M | - | - | - | 18.63M | 11.58M | 6.85M | 9.18M | 33.38M | - | 4.87M | 25.58M | 152.77M | 248.89M |
| Capital Expenditure | -2.21K | -1.99K | -13.43K | -56.12K | -162.69K | -129.70K | -191.97K | -32.19K | -316.49K | -0 | -547.60K | - | -3.36M | -2.05M | -1.54M | -11.72M |
| Free Cash Flow | -4.32M | -4.65M | -2.20M | - | - | - | -14.65M | -14.26M | -14.18M | -6.82M | -10.60M | - | 1.56M | -27.64M | -41.53M | -81.54M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -25.28M | 5.09M | -3.41M | 276.56M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 193 | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -361.7% | -1,074.2% | -1,371.7% | -125.7% | -228.6% | -424.6% | -482.4% | -917.0% | -769.5% | -4,412.6% | - | -1,163.9% | -95.6% | -191.1% | - |
| Net Margin % | - | - | - | - | - | -84.9% | -1,059.5% | -1,767.0% | -129.9% | -233.0% | -470.3% | 91.2% | -908.9% | -760.4% | -4,401.9% | - | -1,137.4% | -88.5% | -181.7% | - |
| ROE % | -63.8% | -113.4% | -249.8% | -16.3% | -59.0% | -69.4% | -42.3% | 1,662.4% | 99.5% | 1,246.1% | 469.8% | 21.7% | -329.1% | -111.7% | -48.4% | - | -246.2% | -98.6% | -27.8% | -34.4% |
| ROCE % | - | - | - | - | -242.4% | -589.7% | -42.9% | -198.1% | -82.1% | -132.2% | -122.6% | -88.1% | -191.8% | -75.7% | -43.3% | - | -112.0% | -87.7% | -28.5% | -33.8% |
Shareholding Pattern
Insiders
9.47%
Institutions
59.70%
Public Float
65.94%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 6.59% | 3.82M | $114.41M |
| 2 | Blackrock Inc. | 5.91% | 3.42M | $102.52M |
| 3 | Tang Capital Management, LLC | 5.87% | 3.40M | $101.86M |
| 4 | State Street Corporation | 3.77% | 2.18M | $65.37M |
| 5 | Vanguard Capital Management LLC | 3.50% | 2.03M | $60.75M |
| 6 | RA Capital Management, L.P. | 2.60% | 1.51M | $45.18M |
| 7 | Geode Capital Management, LLC | 1.93% | 1.12M | $33.51M |
| 8 | Jones Hill Capital LP | 1.57% | 909.21K | $27.24M |
| 9 | Goldman Sachs Group Inc | 1.57% | 911.98K | $27.32M |
| 10 | Point72 Asset Management, L.P. | 1.42% | 821.18K | $24.60M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CAPR
No recent headlines available.